Abstract
Knowledge of the safety profile of drugs prior to marketing is limited because of the small and selective groups of individuals included in clinical trials. A life-cycle approach to surveillance...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
